Targeting RAS–ERK signalling in cancer: promises and challenges
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of single agent therapies targeting individual RAS effector pathways is limited”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“Determinants of primary resistance are not the same in different tumor types that up-regulate various RTKs or their ligands in response to pathway inhibition (111-113).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [113]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Cited by
Items 801–900 of 1,000
Tailoring the Treatment of Melanoma: Implications for Personalized Medicine.
Duan, L., Mukherjee, E. M., & Narayan, D. (2015) · PubMed Central · Cited by 9
Zhang, H., Wang, X.-D., Yang, X., CHEN, D., Hao, J., Cao, R., & Wu, X.-Z. (2017) · Oncogene · doi:10.1038/onc.2016.512 · Cited by 7
Implications of the HDAC6-ERK1 feed forward loop in immunotherapy
Zhang, X. M. (2018) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2018/3.1143 · Cited by 5
Liao, Y., Deng, Y., Yu, X., Zhang, P., & Liu, R. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.114174 · Cited by 6
Explaining Response to Drugs Using Pathway Logic
Talcott, C., & Knapp, M. (2017) · Lecture notes in computer science · doi:10.1007/978-3-319-67471-1_15 · Cited by 6
Jeong, H.-R., Kim, J., & Kim, Y. J. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14101158 · Cited by 6
Osorio, E. Y., Medina-Colorado, A. A., Travi, B. L., & Melby, P. C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242337 · Cited by 8
Dissociation of the Signaling Protein K‐Ras4B from Lipid Membranes Induced by a Molecular Tweezer
Li, L., Erwin, N., Möbitz, S., Niemeyer, F. C., Schrader, T. H., & Winter, R. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201901861 · Cited by 8
Ren, C., Wu, L., Zhang, S., Qi, K., Zhang, Y., Xu, J., Ruan, Y., & Feng, M. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae028 · Cited by 5
Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1
Leguay, K., & Kent, O. A. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s496228 · Cited by 7
An Introduction to Cell Signalling Pathways and Their Dysregulation in Cancer
Talath, S., Wali, A. F., El‐Tanani, M., Al-Dhaheri, Y., Jain, P., & Mottershead, R. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_1 · Cited by 9
Integrated Virtual Screening of Anthraquinone Derivatives for Anticancer Drug Discovery
Chua, H. M., Moshawih, S., Kifli, N., Goh, H. P., Ming, L. C., & Goh, K. W. (2025) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416525501261 · Cited by 5
Li, X., Du, Y., Huang, S., Yang, Y., Lu, D., Zhang, J., Chen, Y., Zhang, L., Nan, Y., & Yuan, L. (2023) · Aging · doi:10.18632/aging.204718 · Cited by 5
Rahbæk, L., Cilliers, C., Wegerski, C. J., Nguyen, N., Otten, J. N., Hargis, L. M., Marx, M. A., Christensen, J. G., & Tran, J. Q. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04728-7 · Cited by 5
Wu, X., Zhang, Y., Ding, Y., Yang, J., Song, Z., Lin, S., Zhang, R., Wu, J., & Shen, S. (2025) · Advanced Science · doi:10.1002/advs.202414525 · Cited by 6
Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy
Qin, W., Liu, Z., Huang, M., Liang, L., Gan, Y., Huang, Z., Huang, J., & Wei, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041425 · Cited by 5
Kwon, Y.-J., Kim, D. Y., Kim, U.-I., Kim, S. H., Kim, Y.-H., Kim, K., & Kim, J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116842 · Cited by 5
PANDORA-Seq Unveils the Hidden Small Non-Coding RNA Landscape in Hypopharyngeal Carcinoma
Pu, M., Shi, L., Ma, H., Tao, C., Zhang, Y., Bu, Y., & Ye, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26135972 · Cited by 5
Orué, A., Chavez, V. A., Strasberg–Rieber, M., & Rieber, M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2930-9 · Cited by 5
Jiang, S., Wang, Z., Zhu, T., Jiang, T., Fei, J.-F., Liu, C., Luo, C., Cheng, Y., & Liu, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720619 · Cited by 8
ALV-miRNA-p19-01 Promotes Viral Replication via Targeting Dual Specificity Phosphatase 6
Yan, Y., Chen, S., Liao, L., Gao, S., Pang, Y., Zhang, X., Zhang, H., & Xie, Q. (2022) · Viruses · doi:10.3390/v14040805 · Cited by 5
KAP1 modulates osteogenic differentiation via the ERK/Runx2 cascade in vascular smooth muscle cells
Bai, W., Cheng, M., Jin, J., Zhang, D., Li, L., Bai, Y., & Xu, J. (2023) · Molecular Biology Reports · doi:10.1007/s11033-022-08225-z · Cited by 6
Su, Y., Yi, J., Zhang, Y., Leng, D., Huang, X., Shi, X., & Zhang, Y. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02916-5 · Cited by 7
Hausott, B., Pircher, L., Kind, M., Park, J., Claus, P., Obexer, P., & Klimaschewski, L. P. (2024) · Cells · doi:10.3390/cells13231967 · Cited by 5
Yenigun, V. B., Ucar, V. B., Sari, Z., Azzawri, A. A., Acar, Y. S., Kaplan, M. B., Nergiz, S., & Acar, H. (2024) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2024.111895 · Cited by 6
Molecular Taxonomy and Tumourigenesis of Colorectal Cancer
Biswas, S., Holyoake, D., & Maughan, T. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.11.001 · Cited by 7
Palvai, S., More, P. A., Mapara, N., Nagraj, J., Chowdhury, R., & Basu, S. (2015) · ChemNanoMat · doi:10.1002/cnma.201500195 · Cited by 5
Previtali, V., Trujillo, C., Boisson, J.-C., Khartabil, H. K., Hénon, É., & Rozas, I. (2017) · Physical Chemistry Chemical Physics · doi:10.1039/c7cp05038k · Cited by 5
Reduction of mitomycin C resistance in human bladder cancer T24 cells by knocking-down ras oncogene
Eldin, O. S., Fouda, A. M., Youssef, A. R., Hamilton, P., Maxwell, P., & Williamson, K. E. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2017.01 · Cited by 5
Maik-Rachline, G., Cohen, I., & Seger, R. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_5 · Cited by 6
Babič, T., Dinić, J., Burić, S. S., Hadžić, S., Pešić, M., Radojkovic, D. P., & Rankov, A. D. (2018) · Acta Biologica Hungarica · doi:10.1556/018.69.2018.4.3 · Cited by 6
Liu, J., Zheng, Y., Gao, Y., Quan, Z., Qiao, B., Luo, L., Li, T., Duan, L., Yang, J., Luo, C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00075 · Cited by 5
RetractedKRAS , NRAS , and BRAF mutations in plasma cell myeloma at a single Korean institute
Kim, Y., Park, S., Min, C., Lee, D., Son, J., Jo, S. J., Han, E., Han, K., & Kim, M. (2020) · Blood Research · doi:10.5045/br.2020.2020137 · Cited by 7
Hua, W.-J., Hwang, W., Yeh, H. H., Lin, Z., Hsu, W.-H., & Lin, T. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129291 · Cited by 7
RAS mutations – for better or for worse in multiple myeloma?
Leich, E., & Steinbrunn, T. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1065984 · Cited by 5
You, X.-H., Dou, L., Tan, M., Xiong, X., & Sun, Y. (2024) · Life Medicine · doi:10.1093/lifemedi/lnae023 · Cited by 4
Athanasopoulou, K., Adamopoulos, P. G., Tsiakanikas, P., & Scorilas, A. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01648-4 · Cited by 4
Mass spectrometry-based proteomics in glioblastoma – current understanding and future impact
Asija, S., Bhat, S., Chatterjee, A., Chekuri, G., Purwar, R., & Goda, J. S. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149890 · Cited by 4
AR/ERK co-targeting triggers ferroptosis via FOXC2 in triple-negative breast cancer
Zhao, Y., Xu, C., Liu, Y., Zhu, Y., Fan, L., Gao, F., Liang, X., Shi, Y., Chen, Y., & Guan, X. (2025) · Science China Life Sciences · doi:10.1007/s11427-025-3044-4 · Cited by 5
Tellenbach, F. L., Seiler, L., Johnson, M. P., Rehrauer, H., Schukla, P., Gómez, J. M. M., Stoffel, C. I., Kamal, A., Dummer, R., Levesque, M. P., et al. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.70062 · Cited by 5
Testosterone and cancers: biological functions, molecular mechanisms and therapy
Zhou, Z., Huang, T., Li, J., Fu, L., Xu, L., Feng, X., Zhang, Z., Pan, H., Qin, K., Zhou, X., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02676-9 · Cited by 4
EPHA3 Could Be a Novel Prognosis Biomarker and Correlates with Immune Infiltrates in Bladder Cancer
Liu, J., Zhou, Z., Jiang, Y., Lin, Y., Yang, Y., Tian, C., Liu, J., Lin, H., & Huang, B. (2023) · Cancers · doi:10.3390/cancers15030621 · Cited by 4
Yoon, C., Lu, J., Jun, Y., Suh, Y., Kim, B., Till, J. E., Kim, J. H., Keshavjee, S., Ryeom, S. W., & Yoon, S. S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11170-0 · Cited by 4
RetractedVuaroqueaux, V., Musch, A., Peille, A.-L., Kelter, G., Weichert, L., Metz, T., Hendriks, H. R., & Fiebig, H. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0221 · Cited by 4
AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis
Oskouian, B., Lee, J. Y., Asgharzadeh, S., Khan, R., Zhang, M., Weisbrod, J. R., Choi, Y., Puri, L., Aguilar, A. E., Zhao, P., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02980-y · Cited by 3
Regorafenib in patients with pretreated advanced melanoma: a single-center case series
Mijnsbrugge, A.-S. V., Cerckel, J., Dirven, I., Tijtgat, J., Vounckx, M., Claes, N., & Neyns, B. (2024) · Melanoma Research · doi:10.1097/cmr.0000000000000977 · Cited by 4
Chen, P., Chen, Y., Wang, Y., Sharma, A., Lukacs‐Kornek, V., Weiher, H., Maria, A. G.-C., & Schmidt‐Wolf, I. G. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-99289-x · Cited by 8
Molekulare und immunhistochemische Diagnostik beim Melanom
Schilling, B., & Griewank, K. (2016) · Der Hautarzt · doi:10.1007/s00105-016-3807-1 · Cited by 4
Mechanisms of Resistance to PI3K and AKT Inhibitors
Castel, P., & Scaltriti, M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_6 · Cited by 5
Liu, J., Ying, M., Wu, B., & Fu, C. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2760979 · Cited by 10
Wu, J.-J., Lee, P.-H., Zheng, Z.-R., Huang, Y.-H., Tseng, J., Hsu, K.-H., Yang, T., Yu, S., Chen, K., & Chang, G. (2022) · Medicine · doi:10.1097/md.0000000000029381 · Cited by 5
Liu, K., Cui, Y., Li, H., Mi, J., Wang, H., Zhuang, Y., Tang, L., Liu, J., Tian, C., Zhang, Z., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104057 · Cited by 4
Singh, A. K., Sreelakshmi, P., Pathak, P., Kumar, A., Singh, H., Yadav, J. P., Verma, A., Grishina, M., & Kumar, P. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073273813231113071010 · Cited by 4
Hoque, N. S., Hossain, M. S., Rahaman, M. A., Chowdhury, R. S., Alam, M. A., Hossain, M. I., & Tama, R. T. (2024) · Journal of Cancer and Tumor International · doi:10.9734/jcti/2024/v14i3260 · Cited by 4
Liu, Y., NI, X. Y., Chen, R., Li, J., & GAO, F. G. (2018) · Oncology Reports · doi:10.3892/or.2018.6351 · Cited by 4
Gong, J., Jiang, Z., Yang, T., & Zhu, Y. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.02.012 · Cited by 4
Zhu, Z., Xiao, T., Chang, X., Hua, Y., & Gao, J. (2019) · Medical Science Monitor · doi:10.12659/msm.912992 · Cited by 4
RetractedThe ERK2 DBP domain opposes pathogenesis of a JAK2V617F-driven myeloproliferative neoplasm
Zhang, Y., Truong, B., Fahl, S. P., Martínez, E., Cai, K. Q., Dulaimi, E., Gong, Y., Liebermann, D. A., Soboloff, J., Dunbrack, R. L., et al. (2022) · Blood · doi:10.1182/blood.2021013068 · Cited by 4
Probing Chromatin Modifications in Response to ERK Signaling
Oksuz, O., & Tee, W. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6424-6_22 · Cited by 4
Acquired palbociclib resistance in KRAS-mutant lung cancer
Sherr, C. J. (2018) · Oncotarget · doi:10.18632/oncotarget.26027 · Cited by 4
Ras-ling with new therapeutic targets for metastasis
Mason, J. A., & Schafer, Z. T. (2017) · Small GTPases · doi:10.1080/21541248.2017.1310650 · Cited by 4
Guterres, A. N., Herlyn, M., & Villanueva, J. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0001894.pub3 · Cited by 5
Optogenetic actuator/biosensor circuits for large-scale interrogation of MAPK signaling dynamicsPreprint
Dessauges, C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.17632/2p9m5jzpzj · Cited by 4
Zheng, J., Wu, J., Xie, L., Huang, Y., Hong, J., & Chen, C. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001695 · Cited by 4
Allosteric site engagement and cooperativity mechanism by PHI1 for BRAFV600E kinase inhibition
Xu, X., Luo, S., Wang, Q., Zhang, E., Liu, J., & Duan, L. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140475 · Cited by 3
Schram, A. M., Boni, V., Adjei, A. A., Olszanski, A. J., Vieito, M., Francis, J. H., Kurman, M. R., Ahsan, J. M., Tomkinson, B., & Garralda, E. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104300 · Cited by 5
Huang, E. J., Parksong, J., Peterson, A. F., Torres, F., Regot, S., & Bever, G. S. (2025) · Journal of Molecular Evolution · doi:10.1007/s00239-025-10254-8 · Cited by 3
Shen, T., Fei, W., Hu, Z., Pang, M., Ma, J., Zhou, T., & Shang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109345 · Cited by 4
Bartl, T., & Castillo‐Tong, D. C. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.104485 · Cited by 5
Inglot, J., Bartusik‐Aebisher, D., Myśliwiec, A., Dynarowicz, K., Paul, A., Xavierselvan, M., & Aebisher, D. (2026) · Biomedicines · doi:10.3390/biomedicines14061314 · Cited by 4
Design, synthesis and evaluation of novel curcumin analog as potential anti-lung cancer agent
Yang, J., Chen, X.-Y., Song, D., & Huang, L. (2022) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2022.2095264 · Cited by 4
Sarkar, S., & Patranabis, S. (2024) · Human Cell · doi:10.1007/s13577-024-01112-8 · Cited by 4
Li, J., & Yu, Y. (2024) · Endocrine · doi:10.1007/s12020-024-03994-y · Cited by 4
Han, D., Kim, S., Lee, S., Moon, Y., Kang, S. J., Yoo, J., Jeong, H. Y., Cho, H. J., Jeon, J. Y., Sim, B. C., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01376-7 · Cited by 3
Tian, J., Cao, X., Jiang, Z., Wang, J., Fan, W., Zhang, S., Zhao, S., & Sun, J. (2024) · Cancer Medicine · doi:10.1002/cam4.70169 · Cited by 3
RetractedLiu, X. Z., Tai, Y., Hou, Y. B., Cao, S., Han, J. Y., Li, M. Y., Zuo, H. X., Xing, Y., Jin, X., & Ma, J. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c04916 · Cited by 4
Shen, C., Cui, T., Yang, L., Gui, L., Corrales-Guerrero, S., Nair, S., Li, H., Karasinska, J. M., Topham, J. T., Renouf, D. J., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf983 · Cited by 4
Chronic Myelomonocytic Leukemia Gold Jubilee
Solary, É., & Itzykson, R. (2021) · Hemato · doi:10.3390/hemato2030026 · Cited by 4
Özenver, N., Kadioglu, O., Fu, Y., & Efferth, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031506 · Cited by 3
Skin Cancer: An Insight on its Association with Aging, Pathogenesis and Treatment Strategies
Sharma, D., Singh, N., & Srivastava, S. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230627154048 · Cited by 4
Activating mutations drive human MEK1 kinase using a gear-shifting mechanism
Patil, K., Wang, Y., Chen, Z., Suresh, K., & Radhakrishnan, R. (2023) · Biochemical Journal · doi:10.1042/bcj20230281 · Cited by 4
SQSTM1/p62 inhibition impairs pro-survival signaling in hypoxic human dendritic cells
Coppola, F., Monaci, S., Falsini, A., Aldinucci, C., Filippi, I., Rossi, D., Carraro, F., & Naldini, A. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119625 · Cited by 3
Zhou, H., Li, G., Kan, L., Yang, M., Liu, Y., Miu, X., Shi, L., Yang, Z., Zheng, X., Chen, H., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30475 · Cited by 3
Predicting treatment outcome using kinome activity profiling in HER2+ breast cancer biopsies
Debets, D. O., de Graaf, E. L., Liefaard, M. C., Sonke, G. S., Lips, E. H., Ressa, A., & Altelaar, M. A. F. (2024) · iScience · doi:10.1016/j.isci.2024.109858 · Cited by 5
Barati, T., Mirzaei, Z., Kahaki, F. A., & Afkhami, H. (2025) · Medical Oncology · doi:10.1007/s12032-025-02828-9 · Cited by 5
Jumaniyazova, E. D., Sentyabreva, A. V., Kosyreva, A. M., & Lokhonina, А. V. (2024) · RUDN Journal of Medicine · doi:10.22363/2313-0245-2024-28-4-413-426 · Cited by 5
Zwaka, T. P. (2017) · Nature · doi:10.1038/nature23102 · Cited by 3
Kahraman, A., Karakulak, T., Szklarczyk, D., & von Mering, C. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/742379 · Cited by 3
Multidimensional single-cell modeling of cellular signalingPreprint
Wade, J. D., Lun, X., Bodenmiller, B., & Voit, E. O. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.15.383711 · Cited by 3
Wu, P., Givskov, M., & Nielsen, T. E. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527674381.ch2 · Cited by 3
AKT drives sustained motility following MEK inhibition via promoting SNAIL and AXL in MDA-MB-231 LM2
Kwon, J., Helfman, D. M., & Kim, M. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.043 · Cited by 2
Wang, Y., Dong, X., Tao, S., Chen, Q., Chen, Y., Zhang, L., Shi, Y., He, Z., Yu, L., & Wang, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1540426 · Cited by 3
Seok, E., Son, M., Lee, S., Cheong, H.-T., & Lee, S. (2025) · Animals · doi:10.3390/ani15142100 · Cited by 4
ALOXE3 expression predicts poor prognosis and modulates immune infiltration in colon adenocarcinoma
Zhao, L., Zhao, L., Ye, S., Jing, S., Yang, H., Qi, Y., Li, Z., Jiang, Z., Yan, X., Wang, K., et al. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03939-3 · Cited by 2
Yan, Z., Du, L.-X., Han, Y., Li, K., Sheng, G., Wang, X., Liu, Y., Zhang, Y., Deng, J., Liu, Z., et al. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01668-0 · Cited by 2
Key signalling pathways in head and neck squamous cell carcinoma: mechanisms and therapeutic targets
Bani-Ahmad, E., Dass, J., & Dass, C. R. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf093 · Cited by 3
Arunsi, U. O., Ezirim, D. C., Arunsi, C. C., Altayyar, A., Eke, G., Jonathan, F. C., Opieh, A. K., Anadi, I. V., Ofoegbu, C. O., Nwankwo, V. C., et al. (2025) · Cancers · doi:10.3390/cancers17213507 · Cited by 2
Onyia, A. F., Lawal, A. O., Ogo, C. N., Nkom, E. S., Lasebikan, N. N., Ayegbusi, O. T., Campos, O. C. D., Rotimi, O. A., Oyelade, J. O., Aliyu, U. M., et al. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.11.012 · Cited by 2
Targeting the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic Opportunities
Vrachas, D., Kosma, E., Giannopoulou, A.-I., Margoni, A., Gargalionis, A. N., El-Habr, E. A., Piperi, C., & Adamopoulos, C. (2026) · Cancers · doi:10.3390/cancers18010156 · Cited by 5
Wang, Z., Huang, J., Liu, J., Li, Y., Wei, C., Gu, Y., Cheng, Y., Xu, Y., Tian, H., & Li, Q. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3291 · Cited by 2
Metadata
- Authors
- Samatar, A. A., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-12
- Volume
- 13
- Issue
- 12
- Pages
- 928-942
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2050573392
- Cited by
- 1,163
- References
- 139
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.